Medically reviewed by Corinne Savides Happel, MD Allergies don't cause psoriasis, but you may be more likely to have ...

The U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical hold on VYNE Therapeutics ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Despite this setback, VYNE has reported no serious adverse events in the subjects enrolled in the study thus far. VYNE’s leadership expressed their commitment to resolving the clinical hold swiftly ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.